Phosphodesterase type 5 inhibitors – clinical efficiency and role in therapy for erectile dysfunction
Z.R. ShodmonovaSamarkand State Medical Institute, Samarkand, UzbekistanR.R. Gafarov GafarovSamarkand State Medical Institute, Samarkand, UzbekistanS AllazovSamarkand State Medical Institute, Samarkand, UzbekistanSh.I. Giyasov GiyasovSamarkand State Medical Institute, Samarkand, Uzbekistan
ABI
Annotatsiya
This article discusses the physiological mechanisms of erection and the pathophysiological basis of erectile dysfunction. Parameters characterizing the features of the pharmacokinetics and pharmacodynamics of drugs from the group of phosphodiesterase type 5 inhibitors (PDE-5i) are presented. The clinical efficacy and possible adverse effects of the most significant PDE-5i are considered. These include sildenafil, tadalafil, vardenafil, udenafil, avanafil. There are also data on less known PDE-5i, which include lodenafil and mirodenafil.
Mavzular
Identifikatorlar
Iqtiboslar va manbalar
0 ta iqtibos0 ta foydalanilgan manba
Koʻrsatkichlar — AkademScholar · Tez orada